Omega-3-acid ethyl esters 90 (Lotriga)

Small molecule

Also known as TAK-085

Approvedregulatory verdict

Evidence outlook

Approved: Hyperlipidemia (JP)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
JP
  • Hyperlipidemia
Product first approved 2012asianscientist.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT01350999 · Takeda
2009-11 – 2011-01 · Hypertriglyceridemia
What this study did
NCT01350973 · Takeda
2009-11 – 2010-12 · Hypertriglyceridemia
What this study did
Phase 4 (2)
Other / comorbidity
NCT02839902 · Takeda
2016-12-27 – 2017-08-30 · Hyperlipidemia
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Omega-3-Acid Ethyl Esters 90 (Lotriga): this drugPhase 3Small moleculeOmega-3 fatty acid (EPA)Partial signal
NCT01350973: Percent Change From Baseline in Triglyceride Level at the Final Visit (Baseline and 12 weeks): TAK-085 2 g -10.93% (Standard Error -14.161 to -7.7062) | TAK-085 4 g -22.65% (Standard Error -25.8436 to -19.4655) vs EPA-E 1.8 g -11.3% (Standard Error -14.6014 to -7.9998)
Icosapent Ethyl (Vascepa)
Approved(overall)
Small moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3)

Upcoming events

No upcoming readouts on record for this asset.